Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer

Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors, 2012, Nature, 490, 61, 10.1038/nature11412

Finn, 2016, Palbociclib and letrozole in advanced breast cancer, N Engl J Med, 375, 1925, 10.1056/NEJMoa1607303

Turner, 2015, Palbociclib in hormone-receptor–positive advanced breast cancer, N Engl J Med, 373, 209, 10.1056/NEJMoa1505270

Cristofanilli, 2016, Lancet Oncol, 17, 425, 10.1016/S1470-2045(15)00613-0

Hortobagyi, 2016, Ribociclib as first-line therapy for HR-positive, advanced breast cancer, N Engl J Med, 375, 1738, 10.1056/NEJMoa1609709

Sledge, 2017, MONARCH-2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy, JCO, 35, 2875, 10.1200/JCO.2017.73.7585

Fu, 2016, Improving the performance of somatic mutation identification by recovering circulating tumor DNA mutations, Cancer Res, 76, 5954, 10.1158/0008-5472.CAN-15-3457

Zheng, 2014, Anchored multiplex PCR for targeted next-generation sequencing, Nat Med, 20, 1479, 10.1038/nm.3729

Lanman, 2015, Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA, PLoS One, 10, e0140712., 10.1371/journal.pone.0140712

Zhang, 2008, Patterns of missplicing caused by RB1 gene mutations in patients with retinoblastoma and association with phenotypic expression, Hum Mutat, 29, 475, 10.1002/humu.20664

Liu, 2012, Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events, Genome Res, 22, 2315, 10.1101/gr.140988.112

Dean, 2010, Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure, Oncogene, 29, 4018, 10.1038/onc.2010.154

Herrera-Abreu, 2016, Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor—positive breast cancer, Cancer Res, 76, 2301, 10.1158/0008-5472.CAN-15-0728

Lefebvre, 2016, Mutational profile of metastatic breast cancers: a retrospective analysis, PLOS Med, 13, e1002201, 10.1371/journal.pmed.1002201

Schiavon, 2015, Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer, Sci Transl Med, 7, 313ra182., 10.1126/scitranslmed.aac7551

Yu, 2014, Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility, Science, 345, 216, 10.1126/science.1253533

Juric, 2014, Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor, Nature, 518, 240, 10.1038/nature13948

Sacher, 2016, Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer, JAMA Oncol, 2, 1014, 10.1001/jamaoncol.2016.0173

Morelli, 2015, Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment, Ann Oncol, 26, 731, 10.1093/annonc/mdv005